Once in the nucleus, STAT1 acts as a transcription factor, facilitating the expression of IFN‐γ‐related genes, including interferon regulatory factor 1 (IRF1).[5] IRF1 is a master regulator of the IFN‐γ‐mediated inflammatory response and antigen presentation and demonstrates a strong association with improved responsiveness to cancer treatment.[6] Therefore, investigations of IFN‐γ/JAK–STAT/IRF1 axis regulation are required to gain insights into the molecular mechanisms associated with responsiveness in cancer immunotherapy. This evidence concerns the gene IFNG and cancer.